SEARCH

SEARCH BY CITATION

References

  • 1
    Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:12061252.
  • 2
    Wang J-G, Staessen JA, Franklin SS, et al. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension. 2005;45:907913.
  • 3
    MacMahon S, Rodgers A. The effects of antihypertensive treatment on vascular disease: reappraisal of the evidence in 1994. J Vasc Med Biol. 1993;4:265271.
  • 4
    Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393404.
  • 5
    Jamerson K, Bakris GL, Dahlöf B, et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007;16:8086.
  • 6
    Ostchega Y, Yoon SS, Hughes J, et al. Hypertension awareness, treatment, and control-Continued disparities in adults: United States, 2005–2006. National Center for Health Statistics, Data Brief #3. 2008 (January): 1–8, 2008.
  • 7
    Ma J, Stafford RS. Screening, treatment, and control of hypertension in US private physician offices, 2003–2004. Hypertension. 2008;51:12751281.
  • 8
    Fang J, Alderman MH, Keenan NL, et al. Hypertension control at physicians’ offices in the United States. Am J Hypertens. 2008;21:136142.
  • 9
    U.S. Department of Health and Human Services. Healthy People 2010: Understanding and Improving Health, 2nd edn. Washington, DC: U.S. Government Printing Office; 2000. Available at: ww.healthypeople.gov/Document/HTML/Volume1/12Heart.htm#_Toc490544222. Accessed November 7, 2008.
  • 10
    Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006;19:11901196.
  • 11
    Halpern MT, Khan ZM, Schmier JK, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension. 2006;47:10391048.
  • 12
    Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:11141117.
  • 13
    Tilson HH. Adherence or compliance? Changes in terminology. Ann Pharmacother. 2004;38:161162.
  • 14
    Krousel-Wood M, Thomas S, Muntner P, et al. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004;19:357362.
  • 15
    World Health Organization. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization; 2003. http://www.emro.who.int/ncd/Publications/adherence_report.pdf. Accessed August 1, 2008.
  • 16
    Caro JJ, Salas M, Speckman JL, et al. Persistence with treatment for hypertension in actual practice. Can Med Assoc J. 1999;160:3137.
  • 17
    Bourgault C, Sénécal M, Brisson M, et al. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens. 2005;19:607613.
  • 18
    Perreault S, Lamarre D, Blais L, et al. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother. 2005;39:14011408.
  • 19
    Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med. 2004;1645:722732.
  • 20
    Bramley TJ, Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12:239245.
  • 21
    Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens. 2002;16:569575.
  • 22
    Duru OK, Vargas RB, Kermah D, et al. Health insurance status and hypertension monitoring and control in the United States. Am J Hypertens. 2007;20:348353.
  • 23
    Zhang D, Carlson AM, Gleason PP, et al. Relationship of the magnitude of member cost-share and medication persistence with newly initiated renin angiotensin system blockers. J Manag Care Pharm. 2007;13:664676.
  • 24
    Briesacher BA, Limcangco R, Frech-Tamas F. New-user persistence with antihypertensives and prescription cost-sharing. J Clin Hypertens (Greenwich). 2008;9:831836.
  • 25
    Taira DA, Wong KS, Frech-Tamas F, et al. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Manag Care. 2006;12:678683.
  • 26
    Briesacher BA, Gurwitz JH, Soumerai SB. Patients at-risk for cost-related medication nonadherence: a review of the literature. J Gen Intern Med. 2007;22:864871.
  • 27
    Berlowitz DR, Ash AS, Hickey C, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:19571963.
  • 28
    Siegel D, Lopez J, Meier J. Antihypertensive medication adherence in the Department of Veterans Affairs. Am J Med. 2007;120:2632.
  • 29
    Bautista LE. Predictors of persistence with antihypertensive therapy: results from the NHANES. Am J Hypertens. 2008;21:183188.
  • 30
    Briesacher BA, Andrade SE, Fouayzi H, et al. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28:437443.
  • 31
    Rosamond W, Flegal K, Furier K, et al. Heart disease and stroke statistics: 2008 update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25e146.
  • 32
    Ho PM, Magid DJ, Masoudi FA, et al. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord. 2006;6:48.
  • 33
    Breekveldt-Postma NS, Penning-van Beest FJA, Siiskonen SJ, et al. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin. 2008;24:121127.
  • 34
    Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521530.
  • 35
    Paramore LC, Halpern MT, Lapuerta P, et al. Impact of poorly controlled hypertension on healthcare resource utilization and cost. Am J Manag Care. 2001;7:389398.
  • 36
    McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002;288:28682879.
  • 37
    Hoer A, Gothe H, Khan ZM, et al. Persistence and adherence with antihypertensive drug therapy in a German sickness fund population. J Hum Hypertens. 2007;21:744746.
  • 38
    Hasford J, Schroder-Bernhardi D, Rottenkolber M, et al. Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. Eur J Clin Pharmacol. 2007;36:10551061.
  • 39
    Conlin PR, Gerth WC, Fox J, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther. 2001;23:19992010.
  • 40
    Van Wijk BLG, Klungel OH, Heerdink ER, et al. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens. 2005;23:21012107.
  • 41
    Burke TA, Sturkenboom MC, Lu SE, et al. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens. 2006;24:11931200.
  • 42
    Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20:671681.
  • 43
    Erkens JA, Panneman MMJ, Klungel OH, et al. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf. 2005;14:795803.
  • 44
    Patel BV, Remigio-Baker RA, Mehta D, et al. Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States. J Clin Hypertens (Greenwich). 2007;9:692700.
  • 45
    Elliott WJ, Plauschinat CA, Skrepnek GH, et al. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med. 2007;20:7280.
  • 46
    Wogen J, Kreilick CA, Livornese RC, et al. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm. 2003;9:424429.
  • 47
    Elliott WJ, Meyer PM. One-year discontinuation rates of antihypertensive drugs in clinical practice: a network meta-analysis [abstract]. J Clin Hypertens (Greenwich). 2007;9(suppl A):A210.
  • 48
    Elliott WJ, Meyer PM, Basu S. One-year persistence with initial antihypertensive drug therapy: a comparison of network and Bayesian meta-analyses [abstract]. J Clin Hypertens (Greenwich). 2008;10(suppl A):A113A114.
  • 49
    Marentette MA, Gerth WC, Billings DK, et al. Antihypertensive persistence and drug class. Can J Cardiol. 2002;18:649656.
  • 50
    Degli Esposti E, Sturani A, Di Martino M, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens. 2002;16:439444.
  • 51
    Caro JJ, Speckman JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. Can Med Assoc J. 1999;160:4146.
  • 52
    Grégoire J-P, Moisan J, Guibert R, et al. Determinants of discontinuation of new courses of antihypertensive medications. J Clin Epidemiol. 2002;55:728735.
  • 53
    Ross SD, Akhras KS, Zhang S, et al. Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis. Pharmacotherapy. 2001;21:940953.
  • 54
    Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a Scientific Statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:27612788.
  • 55
    Trenkwalder P. Combination therapy with AT1-receptor blockers. J Hum Hypertens. 2002;16:S17S25.
  • 56
    Ruilope LM, Malacco E, Khyder Y, et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther. 2005;27:578587.
  • 57
    Neutel JM, Franklin SS, Oparil S, et al. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich). 2006;8:850857.
  • 58
    Tedesco MA, Natale F, Calabro R. Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. J Clin Hypertens (Greenwich). 2006;8:634641.
  • 59
    Hasebe N, Kikuchi K, for the NICE Combi Study Group. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens. 2005;23:445453.
  • 60
    Philipp T, Smith TR, Glazer R, et al. Two multi-center, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29:563580.
  • 61
    Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290300.
  • 62
    Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin–angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;138:3048.
  • 63
    Phillips CO, Kashani A, Ko DK, et al. Adverse effects of combination angiotensin II blockers plus angiotensin converting-enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med. 2007;167:19301936.
  • 64
    ONTARGET Investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15471549.
  • 65
    Düsing R. Overcoming barriers to effective blood pressure control in patients with hypertension. Cur Med Res Opin. 2006;22:15451553.